転移性卵巣がん(Metastatic Ovarian Cancer):治療薬開発パイプライン動向(2015年上半期版)

【英語タイトル】Metastatic Ovarian Cancer - Pipeline Review, H1 2015

Global Markets Directが出版した調査資料(GMDHC6421IDB)・商品コード:GMDHC6421IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2015年3月26日
・ページ数:65
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における転移性卵巣がん(Metastatic Ovarian Cancer)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・転移性卵巣がん(Metastatic Ovarian Cancer)の概要
・転移性卵巣がん(Metastatic Ovarian Cancer)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・転移性卵巣がん(Metastatic Ovarian Cancer)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・転移性卵巣がん(Metastatic Ovarian Cancer)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・転移性卵巣がん(Metastatic Ovarian Cancer)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Metastatic Ovarian Cancer – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Metastatic Ovarian Cancer – Pipeline Review, H1 2015’, provides an overview of the Metastatic Ovarian Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Ovarian Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Ovarian Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Ovarian Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Metastatic Ovarian Cancer – Overview 8
Pipeline Products for Metastatic Ovarian Cancer – Comparative Analysis 9
Metastatic Ovarian Cancer – Therapeutics under Development by Companies 10
Metastatic Ovarian Cancer – Therapeutics under Investigation by Universities/Institutes 11
Metastatic Ovarian Cancer – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Metastatic Ovarian Cancer – Products under Development by Companies 14
Metastatic Ovarian Cancer – Products under Investigation by Universities/Institutes 15
Metastatic Ovarian Cancer – Companies Involved in Therapeutics Development 16
Aura Biosciences, Inc. 16
Eisai Co., Ltd. 17
Immune Design Corp. 18
Innate Pharma SA 19
Millennium Pharmaceuticals, Inc. 20
Northwest Biotherapeutics, Inc. 21
Sumitomo Dainippon Pharma Co., Ltd. 22
VG Life Sciences, Inc. 23
Metastatic Ovarian Cancer – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
antigen-presenting dendritic cells (living, autologous) – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
DCVax-Direct – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Drugs for Cancer – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Drugs for Metastatic Ovarian Cancer – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
E-7449 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
G-305 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
hydroxychloroquine + sorafenib tosylate – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
IPH-2201 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LV-305 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
orteronel – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SM-276001 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Stem Cell Therapy for Oncology – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Metastatic Ovarian Cancer – Recent Pipeline Updates 50
Metastatic Ovarian Cancer – Dormant Projects 62
Metastatic Ovarian Cancer – Discontinued Products 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

[List of Tables]
Number of Products under Development for Metastatic Ovarian Cancer, H1 2015 8
Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Metastatic Ovarian Cancer - Pipeline by Aura Biosciences, Inc., H1 2015 16
Metastatic Ovarian Cancer - Pipeline by Eisai Co., Ltd., H1 2015 17
Metastatic Ovarian Cancer - Pipeline by Immune Design Corp., H1 2015 18
Metastatic Ovarian Cancer - Pipeline by Innate Pharma SA, H1 2015 19
Metastatic Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 20
Metastatic Ovarian Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2015 21
Metastatic Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 22
Metastatic Ovarian Cancer - Pipeline by VG Life Sciences, Inc., H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Assessment by Combination Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 29
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 33
Metastatic Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2015 50
Metastatic Ovarian Cancer - Dormant Projects, H1 2015 62
Metastatic Ovarian Cancer - Discontinued Products, H1 2015 63

[List of Figures]
Number of Products under Development for Metastatic Ovarian Cancer, H1 2015 8
Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Top 10 Targets, H1 2015 26
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Top 10 Routes of Administration, H1 2015 30
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31
Number of Products by Top 10 Molecule Types, H1 2015 32
Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

【掲載企業】

Aura Biosciences, Inc.
Eisai Co., Ltd.
Immune Design Corp.
Innate Pharma SA
Millennium Pharmaceuticals, Inc.
Northwest Biotherapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
VG Life Sciences, Inc.

★調査レポート[転移性卵巣がん(Metastatic Ovarian Cancer):治療薬開発パイプライン動向(2015年上半期版)] (コード:GMDHC6421IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[転移性卵巣がん(Metastatic Ovarian Cancer):治療薬開発パイプライン動向(2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆